samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy

Cellares



  • Second industry partner to enter a strategic relationship with Cellares for advancement of a closed, automated, and scalable cell therapy manufacturing system
  • Poseida Therapeutics to provide insight into autologous and allogeneic CAR-T workflows, as well as emerging programs that include TCR-T, genetically modified NK cells, and other cell therapy manufacturing workflows

SOUTH SAN FRANCISCO – July 14, 2021Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today announced that Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, has joined its Early Access Partnership Program (EAPP). Poseida is the third organization to participate in Cellares’ EAPP, following industry partner PACT Pharma and academic partner Fred Hutchinson Cancer Research Center.

Cellares initiated the EAPP in 2020 to provide participants with visibility and early access to Cellares’ Cell Shuttle, a next generation cell therapy manufacturing platform enabling closed, automated, and scalable production of cell therapies. By entering the program, Poseida is helping advance the Cell Shuttle’s development, range of use, and applicability via insight and experience with respect to manufacturing workflows for a variety of autologous and allogeneic cell therapies.

“We’re thrilled to have Poseida Therapeutics on board to help broaden the possibilities for our Cell Shuttle platform,” said Cellares co-founder and chief executive officer Fabian Gerlinghaus. “Poseida’s tremendous expertise in the cell therapy space, especially spanning a diverse range of therapeutic modalities, is a huge boon to our developmental efforts. We anticipate our work with Poseida to demonstrate the Cell Shuttle’s adaptability for multiple cell therapy modalities, particularly CAR-T cells.”

Poseida currently has two autologous CAR-T product candidates in the clinic, including P-BCMA-101, for patients with relapsed/refractory multiple myeloma, and P-PSMA-101, for patients with metastatic castrate-resistant prostate cancer. The company, which completed an initial public offering in July 2020, also has off-the-shelf versions of both therapies in development, and is exploring TCR-T, anti-c-kit CAR-T, induced pluripotent stem cells (iPSCs), and genetically modified hematopoietic stem cells (HSCs) and NK cells. Immunotherapy pioneer and distinguished oncologist Carl June, M.D., an advisor to Cellares who helped guide the development of the Cell Shuttle, recently joined Poseida’s Immuno-Oncology Scientific Advisory Board.

“The flexibility of the Cell Shuttle matches the breadth of approaches we are developing at Poseida,” said Kerry Ingalls, Chief Operating Officer at Poseida. “To work across our cell therapy portfolio, an automated manufacturing system should be capable of reliably producing a range of therapies autologous and allogeneic CAR-T and in both solid and hematological cancers, for research and at scale for clinical trials and, ultimately, commercial applications. By joining forces with Cellares, we believe we can leverage the Cell Shuttle’s capabilities to help support our overall manufacturing strategy, further advancing cell therapy manufacturing.”

As part of Cellares’ EAPP, Poseida will evaluate the Cell Shuttle prototypes and provide data and written feedback relevant to its function and performance. This will include user studies that assess the Cell Shuttle’s hardware and software, product requirements, release criteria, and process workflows to help ensure product-market fit.

About The Cell Shuttle

The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run the exact processes specified for their cell therapy. Compared with currently available cell therapy manufacturing methods, this next-generation platform enables a three-fold reduction in process failure rates and is capable of producing 10+ patient doses in parallel, which increases manufacturing scalability by an order of magnitude. This will reduce the per-patient manufacturing cost by up to 70 percent for most processes.

About Cellares Corporation

Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies that are more affordable and widely available to patients in need. With Cellares’ proprietary platform—the Cell Shuttle—biopharma companies, academic research centers and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale. The company is headquartered in South San Francisco, Calif. For more information visit www.cellares.com.
phone (833) 235-5273
web www.cellares.com
email South San Francisco, California
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Qatar Airways Cargo and ECS Group celebrate one year of serving Lyon

Since its first flight on 17SEP20, the leading international cargo airline, together with ECS Group, the world’s largest integrated GSSA, has flown more than 5 million kilos out of Lyon, France
More info >>


White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement